To determine whether radiomic features extracted from normal endocrine organs, when combined with clinical variables, can capture systemic imaging signatures predictive of clinical progression in patients with PSMA-negative prostate cancer.
Bahareh Hatami
Radiopharmaceuticals, Theranostics, and Nuclear Medicine